#AMLsm
Hello, anybody home?
#medtwitter #bmtsm #amlsm
November 17, 2024 at 8:35 PM
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent [Dec 13, 2024] @n_gangat et al. @AjHematology
onlinelibrary.wiley.com/doi/10.1002/... #AMLsm #leusm #PrecisionMedicine
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
The Mayo genetic risk models offer pre-treatment and response-based prognostic tools for newly diagnosed AML treated with Ven-HMA.
onlinelibrary.wiley.com
January 13, 2025 at 3:41 PM
Our 2025 #AMLsm updates is out!
An up to date one stop-shop for diagnosis, risk stratificaion and managment, inlcuding new therapuetic algorithms.
Free access to the full manuscript.
onlinelibrary.wiley.com/doi/full/10....
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Disease Overview Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management o...
onlinelibrary.wiley.com
February 12, 2025 at 6:24 PM
An amazing oral presentation of our #AMLsm #AYA #healthdisparities work by super-star resident Dr. Erin Feliciano 🌟#ASH24 #ASHTrainee #ASHKudos @ash-hematology.bsky.social

A 🧵 on some of the highlights of our findings:

1/x
December 8, 2024 at 6:40 PM
Come check out the oral presentation of Evolution of survival disparities among #AYA patients with #AMLsm by Dr. Feliciano at 9:30am PST at the Grand Hyatt 🩸 Some behind the scenes prep from today! #ASH24 #ASHKudos #ASHTrainee @ash-hematology.bsky.social
December 8, 2024 at 5:02 PM
From Blood Cancer Discovery: Intra-Leukemic Interactions Shape #AML Chemoresistance buff.ly/Zl42183

Intra-leukemic interferon signaling suppresses the expansion of leukemic subpopulations and contributes to chemoresistance in several experimental models of AML using primary patient samples. #AMLsm
January 22, 2026 at 5:06 PM
From the January issue of Blood Cancer Discovery: Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency buff.ly/mL0KS6a
#AMLsm
January 19, 2026 at 10:43 PM
My colleague @fergutierrezro1 giving an excellent talk at #ESHBMFS2024 on the clinical implications of clonal hematopoiesis in #telomere biology disorders 🧬; dependent on specific mutation with U2AF1, TP53, and chr1+ associated with #MDSsm and #AMLsm.
November 16, 2024 at 1:28 PM
Outstanding presentation on trial of AZA + Ven in younger #AMLsm adults by @DanPollyea #ASH24. Proud to be part of this collaboration @SylvesterCancer @UMiamiHealth! ORR 69%, MRD- 64% @ash-hematology.bsky.social
December 10, 2024 at 1:12 AM
Excited to run into #AMLSM stars @anand-88-patel.bsky.social & our own Dr Madelyn Burkart from @AtriumHealthWFB Comprehensive Cancer Center at #ASH24! @AtriumHealth @LevineCancer @WakeCancer @wakeforestmed @UChicagoLeuk @UCCancerCenter @bkragonmd.bsky.social
December 8, 2024 at 10:03 PM
In recognition of #AMLWorldAwarenessDay, the NCRI AML18 trial reports DAGO2 induction is superior to CPX-351 for older patients without adverse-risk cytogenetics. 🩺 With @bloodjournals.hematology.org.

Read the review: https://bit.ly/3OEKzQ7

#AMLsm #KnowAML #Leukemia
April 21, 2026 at 7:26 PM
🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia
November 11, 2025 at 10:01 AM
In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.

Watch here:

👉 buff.ly/HbJTfmF 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky
November 2, 2025 at 4:01 PM
Want to hear highlights from #iwAL25?🩸

Check out our fantastic roundtable discussion with leading experts Harry Erba, Thomas Cluzeau, Marina Konopleva, & Aditi Shastri by clicking here:

👉 buff.ly/wtheBJa 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
October 21, 2025 at 1:04 PM
Want to hear about the evolving role of menin inhibitors in AML?🩸

Don't miss our roundtable discussion on this topic from #iwAL25, featuring leading experts Naval Daver, @leukdocjz.bsky.social, Eytan Stein, & Amir Fathi.

Watch here: 👉 buff.ly/iaEfMsV

#AMLsm #Leusm #HemOnc #BloodSky #HemeSky
October 15, 2025 at 5:00 PM
#iwAL25 | Charlie Craddock answers YOUR transplantation questions in a special Ask the Expert session!

Watch here:

👉 buff.ly/TRqoc4q%F0%9...

#HemOnc #ImmunoOnc #AMLsm #BMTsm #Leusm #BloodSky #HemeSky #MedSky
October 11, 2025 at 1:03 PM
At #iwAL25, leading experts Mark Levis, Eunice Wang, and Sanam Loghavi participated in a thought-provoking debate about the value and utility of MRD in the management of adults with newly diagnosed AML.🩸

Watch it here: 👉 buff.ly/XfMfsmQ

#AMLsm #Leusm #MRD #HemOnc #BloodSky #HemeSky #MedSky
October 5, 2025 at 2:01 PM
🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
October 1, 2025 at 5:00 PM
Today is #WorldLeukemiaDay.🩸

Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ

Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧

#AMLsm #CLLsm #ALLsm #Leusm
September 4, 2025 at 3:03 PM
🩸 Today is World #Leukemia Day 🌎

🎥 Musa Yilmaz of @mdanderson.bsky.social discusses the critical role of MRD monitoring in patients with FLT3-mutated AML, as achieving MRD negativity is associated with a lower risk of relapse.

Learn more: 👉 buff.ly/ZYTnlpy

#WorldLeukemiaDay #AMLsm #HemOnc
September 4, 2025 at 9:01 AM
🎥 Guenther Koehne presents the early findings from the Phase I/II study of donor-derived anti-CD33 CAR T-cells in patients with R/R AML following alloSCT:

👉 buff.ly/ekvp1qv 👈

#AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #BloodSky #HemeSky #MedSky
August 31, 2025 at 2:01 PM
🎥 Shaun Fleming presents early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with R/R AML or HR-MDS:

👉 buff.ly/GIoMPtN 👈

#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
August 26, 2025 at 4:42 PM
At #EHA2025, Harry Erba of @dukecancer.bsky.social outlined the updated results from the Phase III QuANTUM-Wild trial evaluating quizartinib combined with chemotherapy and as single-agent maintenance in newly diagnosed FLT3-ITD-negative AML.

Watch here:

👉 buff.ly/hMASdPZ 👈

#AMLsm #Leusm #CTSM
August 25, 2025 at 3:02 PM
In an interview from #EHA2025, Musa Yilmaz of @mdanderson.bsky.social speaks on the efficacy of the triplet combination of decitabine, venetoclax, & quizartinib in patients with newly diagnosed FLT3-ITD–mutated AML.

Watch now:

🎥 buff.ly/LJGCKLC

#AMLsm #Leusm #Leukemia #CTSM #HemOnc #BloodSky
August 18, 2025 at 4:42 PM
Watch our recent interview from #EHA2025 with Andrius Žučenka to hear about ADVANCED, a novel conditioning regimen for alloSCT in patients with adverse-risk AML.

Click here:

👉 buff.ly/nhZNbv8 👈

#AMLsm #Leusm #Leukemia #BMTsm #HemOnc #BloodSky #HemeSky #MedSky
August 7, 2025 at 3:02 PM